Time Required to Dissolve Urate Deposits
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 250 people, planned
- Started
- 24 Sept 2024
- Expected to end
- 24 Sept 2032
- Type of study
- Observational
- Treatments tested
- Standard X-Rays
- Ultrasound
- DECT of feet
- DNA sample
- Serum collection
- Record updated
- 19 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age over 18 years
- Gout according to the ACR/Eular 2015 criteria
- SUA levels greater than 60 mg/L
- US score (MTP1s, knees) ≥2/24
- Informed consent Dated and signed voluntarily
Who cannot take part
- Ongoing urate lowering therapy
- Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases
- Pregnant or breast-feeding women
- No affiliation to the French National Social Security System
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gout is characterized by episodes of acute arthritis of the lower limbs due to intermittent activation of innate immunity in the joints where urate crystals have formed. These crystals occur when serum urate (SUA) levels have been above 70 mg/L for many years. They can be dissolved by lowering SUA levels to at least 60 mg/L (treat-to-target - T2T - strategy). Once the crystals are dissolved, patients are no longer symptomatic and are considered to be in remission (treat-to-dissolve - T2D - strategy).
Read full original descriptionShow less
The presence of crystals and their dissolution during treatment can be monitored by repeated ultrasound (US) scans of the feet and knees.
The time required for complete dissolution varies from patient to patient. ReViGore40 is a cohort designed to i) determine the time to complete dissolution of urate deposits in joints when SUA levels are maintained below 40 mg/L, ii) determine the factors (clinical, biological, genetic) associated with the time required for complete dissolution of urate deposits within joints.
The group in the trial
- Gout patients treated according to a Treat-to-Dissolve strategy
Patients initiated with ULT (urate target less than 40 mg/L), and followed every 6 months with Ultrasound until complete urate dissolution
Treatment: Standard X-Rays, Ultrasound, DECT of feet, DNA sample, and Serum collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Time Required to Dissolve Urate Deposits in Patients With Gout
- Record updated
- 19 February 2026